Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Roth Capital raised their Q1 2016 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a report issued on Monday, Zacks Investment Research reports. Roth Capital analyst J. Pantginis now expects that the brokerage will post earnings of ($0.34) per share for the quarter, up […]
